ATOMO DIAGNOSTICS LIMITED — Capital/Financing Update 2021

Oct 4, 2021

==> picture [182 x 52] intentionally omitted <==

ASX Announcement

5 October 2021

Atomo and Access Bio Renegotiate Supply Agreements

Atomo Diagnostics Limited (ASX:AT1) ( Atomo ) and US-based diagnostics specialist, Access Bio LLC ( Access Bio ), today announced a restructuring of their commercial relationship to reflect the evolving structural changes in the COVID-19 diagnostics market.

Under the new agreement, which has immediate effect and expires on 31 December 2022, Atomo will receive from Access Bio a one-off fee considered by Atomo to be material and replacing any payments due to Atomo under the existing agreements. The new agreement also provides Atomo the right, but not the obligation, to purchase at a fixed price per unit up to 10 million COVID-19 Rapid Antigen tests[1] (Atomo branded) between now and the end of CY22, for use in professional settings in Australia and New Zealand only. This test was listed on the ARTG by the TGA in October 2020, following the announcement of Atomo’s supply agreement with Access Bio for rapid antigen testing dated 29 September 2020, and is currently being sold by Atomo in the Australian market in a number of channels.

Further, Atomo has the right, but not the obligation, to purchase at a fixed price per unit up to 10 million (Atomo branded) COVID-19 Rapid Antigen Self-Tests during CY22 for sale in the Australian market only. Access Bio’s self-test has received Emergency Use Authorization (EUA) from the US FDA and will be delivered to Atomo as an Atomo branded product. Atomo intends to now make an application to the TGA for this self-test to be listed on the ARTG for self-test use in Australia (subject to TGA approval).

Conditional on Access Bio meeting the one-off fee obligation and certain product supply requirements under the new agreement, the existing antibody agreement between Access Bio and Atomo announced to ASX on 28 July 2020 (for supply of Atomo’s Galileo devices to Access Bio) and the existing OEM agreement between the parties dated 22 December 2017 (related to Access Bio commercialising their own HIV professional use test for LMIC global health markets) will both terminate.

1 COVID-19 rapid testing detects SARS-COV-2, the virus that causes COVID-19

==> picture [182 x 52] intentionally omitted <==

The new agreement enables the parties to better align themselves to meet the opportunities resulting from changes in the diagnostic landscape in FY22. The termination of Atomo’s OEM agreement with Access Bio will in no way affect Atomo’s current HIV business where Atomo is the listed manufacturer of its own Atomo HIV Self-Test and AtomoRapid HIV professional use tests across LMIC and developed healthcare markets.

For more information, please contact:

Jane Lowe John Kelly IR Department Atomo Diagnostics Limited jane.lowe@irdepartment.com.au john.kelly@atomodiagnostics.com Phone: +61 411 117 774 Phone: +61 401 922 279

This announcement was authorised by John Kelly, Managing Director.

About Atomo

Atomo is an Australian medical device company supplying unique, integrated rapid diagnostic test (RDT) devices and finished tests to the global diagnostic market. Atomo’s patented devices simplify testing procedures and enhance usability for professional users and untrained self-testers. Atomo has supply agreements in place for tests targeting a range of infectious diseases including for HIV, COVID-19, and viral vs bacterial differentiation.

See more at www.atomodiagnostics.com.